When treated with SB939 alone, primary CML progenitors without the BIM deletion polymorphism has a lower IC50 (150nM; Fig 4B) when compared to that of those with the BIM deletion polymorphism (IC50 = 350nM; Fig 4D). This evidence concerns the gene BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive.